A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease
In 2022–2023, unprecedented outbreaks of clades I and IIb monkeypox virus driven by human-to-human transmission demonstrated a need for rapidly scalable and deployable vaccines against orthopoxviruses. BNT166 is a multivalent mpox mRNA vaccine that shows efficacy in multiple preclinical models, supporting its further study in clinical trials.